Calls for proposals: US CDC, UK-China, Wellcome Trust

Dear All: As we head into the Easter and Passover weekend, three new calls for proposals have emerged! Perhaps one of these is for you?

  • The US CDC has released a Broad Agency Announcement (FY2018-OADS-BAA) seeking proposals for projects across a range of areas (diagnostics, transmission, microbiome disruption, resistance genes in the environment, and stewardship). Initial proposals are due 16 April 2018.
  • Via Innovate UK, the UK Department of Health and Social Care (DHSC) and The Chinese Ministry of Science and Technology (MOST) have announced a competition in which collaborations between UK- and China-based partners can access £10 million (UK) and 60 million Renminbi (China). The topics of interest include Chinese medicines, new agents, improved used of existing agents, and diagnostics. The competition window is 3 April 2018 to 6 June 2018.
  • The Wellcome Trust is opening a Request for Proposals for an evaluation of the likelihood of successful development and implementation for vaccines against pathogens with high levels of antimicrobial resistance, including a survey of the product development landscape and market analysis. The evaluation will identify barriers to the development and implementation for these vaccines and provide recommendations on the development of these vaccines. See this link for more details. Proposals are due 16 April 2018.

For the first two, see below my signature for a bit more detail. All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

CDC’s list of areas: 6 categories spanning 35 AMR-focused topics. Go to this link for the full announcement.

  • New diagnostic, sequencing, and metagenomic tools for AR detection and improved antibiotic use
  • International transmission, colonization, and prevention of AR pathogens
  • Domestic transmission, colonization, and prevention of AR pathogens and C. difficile infections
  • Develop human microbiome disruption indices relevant to AR
  • Resistant pathogens and genes in water systems and the environment and their contribution to human infections
  • Improving antibiotic stewardship

Innovate UK – DHSC – MOST areas of interest: Go to this link for the full announcement

  • explore opportunities from traditional Chinese medicine for the treatment or prevention of infectious bacterial diseases in humans or animals
  • advance the discovery of new agents to prevent or treat drug-resistant bacterial infection in humans or livestock. New agents could include small molecule drugs, vaccines, antibodies or other biological products
  • identify new agents that will increase the feed energy conversion in livestock. This should be done without use of antibiotics or hormones
  • use modelling and prospective and retrospective clinical studies to maximise the clinical utility of current antibiotics. Focus especially on those against drug-resistant Gram-negative bacteria. Projects must aim to improve the prognosis of patients with extensively drug-resistant infections
  • improve capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance

Upcoming meetings of interest to the AMR community:

Share

17 April 2023: FREE Masterclass from FDA / CARB-X wants you!

Dear All, Two quick items today. First, FDA have announced an Antimicrobial Drugs Advisory Committee on 17 April 2023 (9a-4.30p ET). The committee will “discuss new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant’s proposed indication is for the treatment of infections due to Acinetobacter baumannii-calcoaceticus complex including multidrug-resistant and

WHO 2023 Pipeline Update: Share Your Preclinical Antibacterial Projects!

Dear All, As you know, WHO updates their preclinical and clinical pipeline summaries at regular intervals. The most current reviews are summarized on https://amr.solutions/pathogens-and-pipelines/. These excellent summaries are invaluable for researchers of all types and are also used to inform policy work. There is now a call to for current information on antibacterial pre-clinical projects. Go here

PASTEUR: Sign a letter to make it happen this year!

Dear All, As all regular readers of this newsletter know, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is THE key to building a vibrant pipeline of products to address the international problem of AMR. PASTEUR came very close to passage at the end of 2022 …

Scroll to Top